Table 1 Characteristics of the population
N (%) | Median | Mean [SD] | |
|---|---|---|---|
Clinical characteristics | |||
Sex: male | 10 (43.5) | ||
Age (years) | 44.2 [± 9.78] | ||
Symptom duration (years) | 7.7 [± 8.5] | ||
Axial involvement | 12(52.2) | ||
Tobacco use | 16 (70) | ||
Treatment | |||
NSAIDs | 18 (78.3%) | ||
TNF blockers* | 4 (17.4%) | ||
Biological results | |||
Sedimentation rate (mm at the first hour) | 14 | 23.3 [± 22.6] | |
CRP (mg/mL) | 8 | 14.4 [± 20.6] | |
ASAS criteria | |||
HLA-B27 | 7 (30.4) | ||
Arthritis | 9 (39.1) | ||
Enthesitis | 8 (38.8) | ||
Uveitis | 2 (8.7) | ||
Dactylitis | 2 (8.7) | ||
Psoriasis | 6 (26.1) | ||
Inflammatory bowel disease | 3 (13.0) | ||
Familial history | 4 (17.4) | ||
Inflammatory back pain | 22 (95.7) | ||
Good response to NSAIDs | 11 (47.8) | ||
Biological inflammation (CRP > 5 mg/L) | 12 (52.2) | ||
Clinical evaluation scores** | |||
BASFI | 61.5 | 59.3 [± 23.0] | |
BASDAI | 5.88 | 5.45 [± 2.57] | |
BASMI | 3 | 2.9 [± 2.0] | |
ASDAS | 3 | 3.3 [± 0.9] | |